Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma	Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, neoplasm	Recruiting	Phase 2	2025-02-19		NCT06151106

8 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Dongguan People's Hospital	32
Fujian Cancer Hospital	114
Huizhou Municipal Central Hospital	21
Shanxi Province Cancer Hospital	43
Sun Yat-sen University	606
The First Affiliated Hospital of Xiamen University	107
The First Affiliated Hospital with Nanjing Medical University	319
Zhangzhou Affiliated Hospital of Fujian Medical University	11

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
The First Affiliated Hosptial of Xiamen University	Xiamen	China	1